CRISPR Competitors

Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of CRISPR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of CRISPR Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
67.5572.5477.53
Details
Intrinsic
Valuation
LowReal ValueHigh
64.0593.2598.24
Details
Naive
Forecast
LowNext ValueHigh
71.4476.4381.41
Details
16 Analysts
Consensus
LowTarget PriceHigh
100.00160.69220.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CRISPR Therapeutics. Your research has to be compared to or analyzed against CRISPR Therapeutics' peers to derive any actionable benefits. When done correctly, CRISPR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in CRISPR Therapeutics.

CRISPR Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CRISPR Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CRISPR and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of CRISPR Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

CRISPR Therapeutics Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between CRISPR Stock performing well and CRISPR Therapeutics company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze CRISPR Therapeutics' multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
TWTR 2.05  0.07  0.02  0.15  3.33  0.0243 (1.94)  4.00 (5.10)  17.65 
MSFT 1.54  0.07  0.05  0.13  1.89  0.05 (1.69)  2.98 (4.10)  7.83 
UBER 3.40  0.31  0.08  0.27  3.97  0.08 (3.55)  6.40 (7.08)  21.38 
F 2.43  0.16  0.07  0.16  2.86  0.08 (2.54)  5.15 (4.03)  12.24 
T 1.11 (0.14)  0.00 (0.13)  0.00 (0.10)  0.00  2.00 (2.45)  10.60 
A 1.82  0.19  0.11  0.25  1.80  0.09 (2.11)  4.88 (3.15)  8.98 
CRM 2.37  0.08  0.05  0.13  2.77  0.0443 (2.60)  5.77 (4.63)  16.84 
JPM 1.45 (0.03) (0.01)  0.05  1.54 (0.008) (1.73)  3.03 (2.34)  10.79 
MRK 0.96 (0.01) (0.05)  0.05  1.21 (0.045) (0.99)  2.11 (2.50)  6.96 
XOM 1.94  0.02  0.00  0.10  2.59  0.0042 (1.83)  3.33 (3.96)  10.43 

Cross Equities Net Income Analysis

Compare CRISPR Therapeutics and related stocks such as Walt Disney Net Income Over Time
Select Fundamental

2010201120122013201420152016201720182019202020212022
DIS4.8 B9.4 B9.4 B9.4 B9.4 B9.4 BBBBBBB7.5 B

CRISPR Therapeutics and related stocks such as Walt Disney Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in CRISPR Therapeutics financial statement analysis. It represents the amount of money remaining after all of CRISPR Therapeutics AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income to Non Controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends Income Statement Impact.

CRISPR Therapeutics Competitive Analysis

The better you understand CRISPR Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CRISPR Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CRISPR Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CRSP
DIS
 0.57 
 72.15 
 0.11 
 122.67 
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Current Valuation
Cash Flow from Operations
Operating Margin
Retained Earnings
Current Asset
Five Year Return
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Price to Earnings To Growth
Current Liabilities
Total Asset
Short Ratio
Last Dividend Paid
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

CRISPR Therapeutics Competition Performance Charts

Complement your CRISPR Therapeutics position

In addition to having CRISPR Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Growth Thematic Idea Now

Tech Growth
Tech Growth Theme
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 65 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
View All  Next Launch
Continue to CRISPR Therapeutics Correlation with its peers. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CRSP
 Stock
  

USD 72.15  0.41  0.57%   

CRISPR Therapeutics competes with Disney; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing CRISPR Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of CRISPR Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of CRISPR Therapeutics competition on your existing holdings. Continue to CRISPR Therapeutics Correlation with its peers.
  
As of 18th of August 2022, Return on Average Assets is likely to grow to 0.16. Also, Return on Average Equity is likely to grow to 0.17. CRISPR Therapeutics Average Assets are very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Average Assets of 2.61 Billion. As of 18th of August 2022, Tangible Asset Value is likely to grow to about 3 B, while Tangible Assets Book Value per Share are likely to drop 30.69.